Brian Abrahams
Stock Analyst at RBC Capital
(2.25)
# 2,701
Out of 5,163 analysts
452
Total ratings
42.5%
Success rate
-4.04%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Initiates: Outperform | $52 | $25.42 | +104.56% | 1 | Mar 9, 2026 | |
| APGE Apogee Therapeutics | Maintains: Sector Perform | $83 → $82 | $71.90 | +14.05% | 4 | Mar 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $745 → $765 | $745.77 | +2.58% | 36 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Sector Perform | $12 → $13 | $17.13 | -24.11% | 5 | Mar 2, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Sector Perform | $18 → $6 | $5.09 | +17.88% | 6 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $31 → $30 | $20.61 | +45.56% | 5 | Feb 26, 2026 | |
| GLPG Galapagos NV | Maintains: Sector Perform | $32 → $33 | $31.71 | +4.07% | 14 | Feb 25, 2026 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $11 → $12 | $9.21 | +30.29% | 13 | Feb 20, 2026 | |
| PTCT PTC Therapeutics | Maintains: Sector Perform | $87 → $82 | $64.49 | +27.15% | 24 | Feb 20, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $546 → $541 | $469.34 | +15.27% | 58 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $177 | $129.78 | +36.38% | 25 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $95 → $92 | $92.54 | -0.58% | 25 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $103 → $118 | $144.99 | -18.62% | 35 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $217 → $233 | $181.55 | +28.34% | 42 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $13 | $8.22 | +58.15% | 20 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $30 | $15.04 | +99.47% | 1 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $40 | $14.95 | +167.56% | 2 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $36 | $18.06 | +99.34% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $103 | $79.03 | +30.33% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $37.32 | -35.69% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $7 | $3.00 | +133.33% | 7 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $13.01 | +69.10% | 6 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $53 | $9.41 | +463.23% | 9 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $1.5 → $1 | $0.85 | +17.65% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.35 | +48.15% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $58 | $55.23 | +5.02% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $7.85 | +142.04% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $16.40 | +40.24% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $18.75 | +348.00% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $156.08 | -8.38% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $28.62 | +39.76% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $12.70 | +18.11% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $3.69 | +143.90% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $21.34 | - | 4 | Dec 4, 2017 |
Pharvaris
Mar 9, 2026
Initiates: Outperform
Price Target: $52
Current: $25.42
Upside: +104.56%
Apogee Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $83 → $82
Current: $71.90
Upside: +14.05%
Regeneron Pharmaceuticals
Mar 2, 2026
Maintains: Sector Perform
Price Target: $745 → $765
Current: $745.77
Upside: +2.58%
MoonLake Immunotherapeutics
Mar 2, 2026
Maintains: Sector Perform
Price Target: $12 → $13
Current: $17.13
Upside: -24.11%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Sector Perform
Price Target: $18 → $6
Current: $5.09
Upside: +17.88%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $31 → $30
Current: $20.61
Upside: +45.56%
Galapagos NV
Feb 25, 2026
Maintains: Sector Perform
Price Target: $32 → $33
Current: $31.71
Upside: +4.07%
Prothena Corporation
Feb 20, 2026
Maintains: Sector Perform
Price Target: $11 → $12
Current: $9.21
Upside: +30.29%
PTC Therapeutics
Feb 20, 2026
Maintains: Sector Perform
Price Target: $87 → $82
Current: $64.49
Upside: +27.15%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Outperform
Price Target: $546 → $541
Current: $469.34
Upside: +15.27%
Feb 12, 2026
Maintains: Outperform
Price Target: $180 → $177
Current: $129.78
Upside: +36.38%
Feb 11, 2026
Maintains: Sector Perform
Price Target: $95 → $92
Current: $92.54
Upside: -0.58%
Feb 11, 2026
Maintains: Sector Perform
Price Target: $103 → $118
Current: $144.99
Upside: -18.62%
Feb 9, 2026
Maintains: Outperform
Price Target: $217 → $233
Current: $181.55
Upside: +28.34%
Jan 30, 2026
Maintains: Outperform
Price Target: $14 → $13
Current: $8.22
Upside: +58.15%
Jan 29, 2026
Maintains: Outperform
Price Target: $28 → $30
Current: $15.04
Upside: +99.47%
Jan 23, 2026
Maintains: Outperform
Price Target: $33 → $40
Current: $14.95
Upside: +167.56%
Jan 23, 2026
Maintains: Outperform
Price Target: $20 → $36
Current: $18.06
Upside: +99.34%
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $79.03
Upside: +30.33%
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $37.32
Upside: -35.69%
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $3.00
Upside: +133.33%
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $13.01
Upside: +69.10%
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $9.41
Upside: +463.23%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $0.85
Upside: +17.65%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.35
Upside: +48.15%
Nov 4, 2025
Maintains: Outperform
Price Target: $55 → $58
Current: $55.23
Upside: +5.02%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $7.85
Upside: +142.04%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $16.40
Upside: +40.24%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $18.75
Upside: +348.00%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $156.08
Upside: -8.38%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $28.62
Upside: +39.76%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $12.70
Upside: +18.11%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $3.69
Upside: +143.90%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $21.34
Upside: -